NYSE:DPLO - Diplomat Pharmacy Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.48 +0.33 (+1.37 %)
(As of 05/28/2018 06:00 AM ET)
Previous Close$24.48
Today's Range$24.09 - $25.10
52-Week Range$14.23 - $27.78
Volume903,423 shs
Average Volume1.00 million shs
Market Capitalization$1.81 billion
P/E Ratio27.82
Dividend YieldN/A
Beta1.31

About Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy logoDiplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company's primary focus is on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. The company was founded in 1975 and is headquartered in Flint, Michigan.

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
SymbolNYSE:DPLO
CUSIPN/A
Phone888-720-4450

Debt

Debt-to-Equity Ratio0.59
Current Ratio0.88
Quick Ratio0.57

Price-To-Earnings

Trailing P/E Ratio27.82
Forward P/E Ratio26.61
P/E GrowthN/A

Sales & Book Value

Annual Sales$4.49 billion
Price / Sales0.40
Cash Flow$1.8392 per share
Price / Cash13.31
Book Value$10.88 per share
Price / Book2.25

Profitability

EPS (Most Recent Fiscal Year)$0.84
Net Income$15.51 million
Net Margins0.23%
Return on Equity8.80%
Return on Assets4.07%

Miscellaneous

Employees2,419
Outstanding Shares74,130,000

Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) posted its quarterly earnings results on Monday, May, 7th. The company reported $0.20 EPS for the quarter, missing the Zacks' consensus estimate of $0.21 by $0.01. The business earned $1.34 billion during the quarter, compared to analysts' expectations of $1.28 billion. Diplomat Pharmacy had a return on equity of 8.80% and a net margin of 0.23%. The firm's revenue for the quarter was up 24.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.19 earnings per share. View Diplomat Pharmacy's Earnings History.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Diplomat Pharmacy.

What guidance has Diplomat Pharmacy issued on next quarter's earnings?

Diplomat Pharmacy updated its FY18 earnings guidance on Monday, May, 7th. The company provided earnings per share (EPS) guidance of $0.87-$0.97 for the period, compared to the Thomson Reuters consensus estimate of $0.92. The company issued revenue guidance of $5.5-$5.9 billion, compared to the consensus revenue estimate of $5.44 billion.

What price target have analysts set for DPLO?

10 equities research analysts have issued 1 year target prices for Diplomat Pharmacy's shares. Their predictions range from $18.00 to $35.00. On average, they expect Diplomat Pharmacy's stock price to reach $27.2222 in the next twelve months. View Analyst Ratings for Diplomat Pharmacy.

Who are some of Diplomat Pharmacy's key competitors?

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 66)
  • Mr. Gary Rice M.B.A., M.S., R.Ph., RPh, MS, MBA, CSP, Exec. VP of Operations (Age 60)
  • Mr. Jeffrey G. Park, Interim CEO & Director (Age 46)
  • Mr. Joel Saban, Pres (Age 50)
  • Mr. Atul Kavthekar, CFO, Treasurer & Principal Accounting Officer

Has Diplomat Pharmacy been receiving favorable news coverage?

News headlines about DPLO stock have trended somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Diplomat Pharmacy earned a news sentiment score of 0.13 on Accern's scale. They also assigned headlines about the company an impact score of 46.69 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are Diplomat Pharmacy's major shareholders?

Diplomat Pharmacy's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.79%), Frontier Capital Management Co. LLC (5.29%), Dimensional Fund Advisors LP (1.75%), Northern Trust Corp (1.66%), GW&K Investment Management LLC (1.38%) and Cambridge Investment Research Advisors Inc. (1.36%). Company insiders that own Diplomat Pharmacy stock include Atheer A Kaddis, Atul Kavthekar, Jeffrey G Park, Joel Saban and Philip R Hagerman. View Institutional Ownership Trends for Diplomat Pharmacy.

Which institutional investors are selling Diplomat Pharmacy stock?

DPLO stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Cortina Asset Management LLC, BlackRock Inc., Cambridge Investment Research Advisors Inc., JPMorgan Chase & Co., Citigroup Inc., Broadview Advisors LLC and Granite Investment Partners LLC. Company insiders that have sold Diplomat Pharmacy company stock in the last year include Jeffrey G Park and Philip R Hagerman. View Insider Buying and Selling for Diplomat Pharmacy.

Which institutional investors are buying Diplomat Pharmacy stock?

DPLO stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Redwood Investments LLC, Matarin Capital Management LLC, Hood River Capital Management LLC, Palisade Capital Management LLC NJ, Mackay Shields LLC, Frontier Capital Management Co. LLC and State of Wisconsin Investment Board. Company insiders that have bought Diplomat Pharmacy stock in the last two years include Atul Kavthekar, Jeffrey G Park and Joel Saban. View Insider Buying and Selling for Diplomat Pharmacy.

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $24.48.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $1.81 billion and generates $4.49 billion in revenue each year. The company earns $15.51 million in net income (profit) each year or $0.84 on an earnings per share basis. Diplomat Pharmacy employs 2,419 workers across the globe.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (DPLO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  228 (Vote Outperform)
Underperform Votes:  225 (Vote Underperform)
Total Votes:  453
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Diplomat Pharmacy (NYSE:DPLO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Diplomat Pharmacy in the last 12 months. Their average twelve-month price target is $27.2222, suggesting that the stock has a possible upside of 11.20%. The high price target for DPLO is $35.00 and the low price target for DPLO is $18.00. There are currently 4 hold ratings and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldHoldHold
Consensus Rating Score: 2.602.452.362.29
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $27.2222$25.50$24.8636$19.6429
Price Target Upside: 11.20% upside21.26% upside13.53% upside3.00% upside

Diplomat Pharmacy (NYSE:DPLO) Consensus Price Target History

Price Target History for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE:DPLO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightHighView Rating Details
3/8/2018BarclaysInitiated CoverageOverweight ➝ Overweight$27.00MediumView Rating Details
3/2/2018Deutsche BankUpgradeHold ➝ BuyHighView Rating Details
2/27/2018Needham & Company LLCSet Price TargetBuy$28.00HighView Rating Details
2/27/2018Wells Fargo & CoReiterated RatingMarket Perform$21.50 ➝ $25.00HighView Rating Details
2/27/2018Leerink SwannSet Price TargetOutperform ➝ Buy$32.00 ➝ $30.00HighView Rating Details
2/9/2018Lake Street CapitalInitiated CoverageBuy ➝ Buy$35.00HighView Rating Details
1/25/2018Credit Suisse GroupUpgradeUnderperform ➝ Neutral$28.00LowView Rating Details
1/24/2018MizuhoSet Price TargetHold$25.00LowView Rating Details
11/16/2017Robert W. BairdDowngradeOutperform ➝ Neutral$24.00 ➝ $18.00N/AView Rating Details
5/25/2017Bank of AmericaBoost Price TargetNeutral$17.00 ➝ $18.50LowView Rating Details
5/9/2017CowenBoost Price TargetMarket Perform$12.00 ➝ $17.00MediumView Rating Details
11/3/2016Raymond JamesReiterated RatingOutperform ➝ Market PerformN/AView Rating Details
11/3/2016CitigroupDowngradeMarket PerformN/AView Rating Details
11/3/2016Avondale PartnersDowngradeOutperform ➝ Market PerformN/AView Rating Details
(Data available from 5/28/2016 forward)

Earnings

Diplomat Pharmacy (NYSE:DPLO) Earnings History and Estimates Chart

Earnings by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE:DPLO) Earnings Estimates

2018 EPS Consensus Estimate: $0.94
2019 EPS Consensus Estimate: $1.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.19$0.23$0.21
Q2 20182$0.24$0.24$0.24
Q3 20182$0.24$0.24$0.24
Q4 20182$0.24$0.25$0.25
Q1 20191$0.26$0.26$0.26
Q2 20191$0.31$0.31$0.31
Q3 20191$0.31$0.31$0.31
Q4 20191$0.32$0.32$0.32

Diplomat Pharmacy (NYSE DPLO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018$0.23N/AView Earnings Details
5/7/2018Q1 2018$0.21$0.20$1.2827 billion$1.3420 billionViewListenView Earnings Details
2/26/2018Q4 2017$0.16$0.18$1.1668 billion$1.1551 billionViewListenView Earnings Details
11/6/2017Q3 2017$0.15$0.25$1.1602 billion$1.1250 billionViewN/AView Earnings Details
8/7/2017Q2 2017$0.15$0.25$1.1358 billion$1.1265 billionViewListenView Earnings Details
5/8/2017Q1 2017$0.15$0.19$1.0848 billion$1.0787 billionViewListenView Earnings Details
2/28/2017Q416$0.16$0.08$1.18 billion$1.1448 billionViewListenView Earnings Details
11/2/2016Q316$0.24$0.21$1.26 billion$1.1810 billionViewN/AView Earnings Details
8/9/2016Q216$0.21$0.23$1.12 billion$1.0890 billionViewN/AView Earnings Details
5/9/2016Q116$0.18$0.23$984.28 million$995.90 millionViewN/AView Earnings Details
2/29/2016Q415$0.20$0.21$969.70 million$987.00 millionViewListenView Earnings Details
11/3/2015Q315$0.16$0.26$928.86 million$946.90 millionViewN/AView Earnings Details
8/3/2015Q215$0.12$0.16$738.99 million$808.01 millionViewN/AView Earnings Details
5/11/2015Q115$0.08$0.09$629.60 million$625.00 millionViewListenView Earnings Details
3/2/2015Q414$0.06$0.08$603.70 million$603.67 millionViewN/AView Earnings Details
11/10/2014Q3 2014$0.15$595.53 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Diplomat Pharmacy (NYSE:DPLO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Diplomat Pharmacy (NYSE DPLO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 30.20%
Institutional Ownership Percentage: 75.99%
Insider Trading History for Diplomat Pharmacy (NYSE:DPLO)
Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Diplomat Pharmacy (NYSE DPLO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2018Jeffrey G. ParkDirectorSell13,875$24.20$335,775.00View SEC Filing  
3/9/2018Philip R. HagermanDirectorSell2,150,000$20.65$44,397,500.00View SEC Filing  
11/20/2017Atul KavthekarCFOBuy2,000$15.00$30,000.002,000View SEC Filing  
11/20/2017Jeffrey G ParkDirectorBuy3,000$15.46$46,380.007,640View SEC Filing  
11/20/2017Joel SabanPresidentBuy10,000$15.24$152,400.0012,000View SEC Filing  
9/15/2016Atheer A KaddisEVPSell20,000$30.12$602,400.0020,000View SEC Filing  
8/1/2016Atheer A KaddisEVPSell12,325$35.76$440,742.0012,325View SEC Filing  
7/1/2016Atheer A KaddisEVPSell12,325$35.04$431,868.0012,325View SEC Filing  
6/1/2016Atheer A KaddisEVPSell12,325$32.31$398,220.7512,325View SEC Filing  
5/2/2016Atheer A KaddisEVPSell12,325$30.17$371,845.2512,325View SEC Filing  
4/15/2016Atheer A KaddisEVPSell24,650$30.00$739,500.0024,650View SEC Filing  
2/12/2016Atheer A. KaddisEVPSell12,325$30.00$369,750.00View SEC Filing  
12/7/2015Philip R HagermanCEOSell2,300,000$33.60$77,280,000.00View SEC Filing  
12/1/2015Atheer A. KaddisSVPSell12,325$34.75$428,293.75View SEC Filing  
12/1/2015Gary W. KadlecPresidentSell30,000$34.93$1,047,900.00View SEC Filing  
11/3/2015Atheer A. KaddisSVPSell24,650$30.00$739,500.00View SEC Filing  
11/2/2015Gary W. KadlecPresidentSell30,000$28.03$840,900.00View SEC Filing  
10/1/2015Gary W. KadlecPresidentSell30,000$27.66$829,800.00View SEC Filing  
9/8/2015Atheer A. KaddisSVPSell12,325$37.42$461,201.50View SEC Filing  
9/1/2015Gary W. KadlecPresidentSell30,000$38.05$1,141,500.00View SEC Filing  
8/26/2015Sean WhelanCFOSell149,534$38.04$5,688,273.36142,530View SEC Filing  
3/25/2015David C DreyerDirectorBuy1,034$29.00$29,986.00View SEC Filing  
3/25/2015Jeffrey M RoweEVPSell600,000$29.00$17,400,000.00View SEC Filing  
3/25/2015Philip R HagermanCEOSell1,801,000$29.00$52,229,000.00View SEC Filing  
10/9/2014Atheer A KaddisSVPBuy4,000$13.00$52,000.00View SEC Filing  
10/9/2014Jeffrey M RoweEVPSell416,666$13.00$5,416,658.00View SEC Filing  
10/9/2014Philip R HagermanCEOSell2,916,666$13.00$37,916,658.00View SEC Filing  
10/9/2014Sean WhelanCFOBuy2,000$13.00$26,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Diplomat Pharmacy (NYSE DPLO) News Headlines

Source:
DateHeadline
Diplomat Pharmacy Inc (DPLO) Director Sells $335,775.00 in StockDiplomat Pharmacy Inc (DPLO) Director Sells $335,775.00 in Stock
www.americanbankingnews.com - May 25 at 7:38 PM
Head to Head Review: Rite Aid (RAD) vs. Diplomat Pharmacy (DPLO)Head to Head Review: Rite Aid (RAD) vs. Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - May 23 at 11:27 AM
Analyzing CVS Health (CVS) and Diplomat Pharmacy (DPLO)Analyzing CVS Health (CVS) and Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - May 21 at 3:16 PM
Rite Aid (RAD) versus Diplomat Pharmacy (DPLO) Financial AnalysisRite Aid (RAD) versus Diplomat Pharmacy (DPLO) Financial Analysis
www.americanbankingnews.com - May 20 at 7:22 PM
$1.42 Billion in Sales Expected for Diplomat Pharmacy (DPLO) This Quarter$1.42 Billion in Sales Expected for Diplomat Pharmacy (DPLO) This Quarter
www.americanbankingnews.com - May 17 at 3:48 AM
Diplomat Pharmacy Integrates With New LeadershipDiplomat Pharmacy Integrates With New Leadership
finance.yahoo.com - May 15 at 5:20 PM
Head to Head Contrast: Diplomat Pharmacy (DPLO) & CVS Health (CVS)Head to Head Contrast: Diplomat Pharmacy (DPLO) & CVS Health (CVS)
www.americanbankingnews.com - May 15 at 1:43 PM
Zacks: Brokerages Anticipate Diplomat Pharmacy (DPLO) to Post $0.23 EPSZacks: Brokerages Anticipate Diplomat Pharmacy (DPLO) to Post $0.23 EPS
www.americanbankingnews.com - May 15 at 11:34 AM
Your guide to the Trump drug price plan: who it affects and howYour guide to the Trump drug price plan: who it affects and how
www.marketwatch.com - May 15 at 9:16 AM
Contrasting Diplomat Pharmacy (DPLO) and CVS Health (CVS)Contrasting Diplomat Pharmacy (DPLO) and CVS Health (CVS)
www.americanbankingnews.com - May 14 at 11:16 PM
Reviewing Diplomat Pharmacy (DPLO) & CVS Health (CVS)Reviewing Diplomat Pharmacy (DPLO) & CVS Health (CVS)
www.americanbankingnews.com - May 14 at 3:23 PM
FY2018 EPS Estimates for Diplomat Pharmacy (DPLO) Reduced by AnalystFY2018 EPS Estimates for Diplomat Pharmacy (DPLO) Reduced by Analyst
www.americanbankingnews.com - May 11 at 10:52 AM
ARMO Snapped Up, DEPO Soars On Upbeat Forecast, DPLO Gets A New BossARMO Snapped Up, DEPO Soars On Upbeat Forecast, DPLO Gets A New Boss
www.nasdaq.com - May 11 at 9:28 AM
Diplomat Pharmacy (DPLO) New CEO Removes an Overhang - CowenDiplomat Pharmacy (DPLO) New CEO Removes an Overhang - Cowen
www.streetinsider.com - May 11 at 9:28 AM
Equities Analysts Offer Predictions for Diplomat Pharmacys Q2 2018 Earnings (DPLO)Equities Analysts Offer Predictions for Diplomat Pharmacy's Q2 2018 Earnings (DPLO)
www.americanbankingnews.com - May 11 at 9:05 AM
Diplomat Pharmacy (DPLO) Lifted to "Overweight" at JPMorgan ChaseDiplomat Pharmacy (DPLO) Lifted to "Overweight" at JPMorgan Chase
www.americanbankingnews.com - May 10 at 7:51 PM
Why Diplomat Pharmacy Stock Jumped TodayWhy Diplomat Pharmacy Stock Jumped Today
finance.yahoo.com - May 10 at 5:15 PM
Diplomat Pharmacy (DPLO) Given Average Rating of "Hold" by AnalystsDiplomat Pharmacy (DPLO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 10 at 1:11 PM
Diplomat Pharmacy Appoints Brian Griffin as Chief Executive Officer and Chairman of the BoardDiplomat Pharmacy Appoints Brian Griffin as Chief Executive Officer and Chairman of the Board
finance.yahoo.com - May 10 at 9:01 AM
Edited Transcript of DPLO earnings conference call or presentation 8-May-18 12:00pm GMTEdited Transcript of DPLO earnings conference call or presentation 8-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 9:01 AM
Q3 2018 Earnings Forecast for Diplomat Pharmacy Issued By William Blair (DPLO)Q3 2018 Earnings Forecast for Diplomat Pharmacy Issued By William Blair (DPLO)
www.americanbankingnews.com - May 10 at 7:50 AM
Diplomat Pharmacy (DPLO) Raised to Hold at Zacks Investment ResearchDiplomat Pharmacy (DPLO) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - May 9 at 9:42 PM
Diplomat Pharmacys (DPLO) Interim CEO Jeff Park on Q1 2018 Results - Earnings Call TranscriptDiplomat Pharmacy's (DPLO) Interim CEO Jeff Park on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:02 PM
Diplomat Pharmacy in Final Stages of CEO Search ProcessDiplomat Pharmacy in Final Stages of CEO Search Process
finance.yahoo.com - May 8 at 8:52 AM
Diplomat Pharmacy (DPLO) Issues Quarterly  Earnings ResultsDiplomat Pharmacy (DPLO) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 7 at 9:12 PM
Diplomat Pharmacy misses by $0.02, beats on revenueDiplomat Pharmacy misses by $0.02, beats on revenue
seekingalpha.com - May 7 at 5:13 PM
Diplomat Pharmacy (DPLO) Issues FY18 Earnings GuidanceDiplomat Pharmacy (DPLO) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 7 at 5:12 PM
DPLO Crosses Below Key Moving Average LevelDPLO Crosses Below Key Moving Average Level
www.nasdaq.com - May 7 at 5:08 PM
Diplomat Pharmaceuticals: 1Q Earnings SnapshotDiplomat Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 7 at 5:08 PM
Diplomat Announces Strong 1st Quarter Financial ResultsDiplomat Announces Strong 1st Quarter Financial Results
finance.yahoo.com - May 7 at 5:08 PM
Daily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Catalent, Diplomat Pharmacy, and Ironwood PharmaDaily Technical Summary Reports on Generic Drugs Stocks -- Adamas Pharma, Catalent, Diplomat Pharmacy, and Ironwood Pharma
www.bizjournals.com - May 7 at 8:49 AM
Express Scripts (ESRX) & Diplomat Pharmacy (DPLO) Critical AnalysisExpress Scripts (ESRX) & Diplomat Pharmacy (DPLO) Critical Analysis
www.americanbankingnews.com - May 4 at 3:29 PM
Reviewing Express Scripts (ESRX) & Diplomat Pharmacy (DPLO)Reviewing Express Scripts (ESRX) & Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - May 3 at 9:43 PM
Diplomat Pharmacy (DPLO) Cut to "Sell" at Zacks Investment ResearchDiplomat Pharmacy (DPLO) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 2 at 12:36 AM
Diplomat to Participate in 43rd Annual Deutsche Bank Health Care ConferenceDiplomat to Participate in 43rd Annual Deutsche Bank Health Care Conference
finance.yahoo.com - May 1 at 4:51 PM
Diplomat Launches CastiaRx, Industry-Leading Specialty Benefit ManagerDiplomat Launches CastiaRx, Industry-Leading Specialty Benefit Manager
finance.yahoo.com - April 30 at 8:59 AM
Diplomat Pharmacy (DPLO) to Release Earnings on MondayDiplomat Pharmacy (DPLO) to Release Earnings on Monday
www.americanbankingnews.com - April 30 at 6:38 AM
 Analysts Expect Diplomat Pharmacy (DPLO) Will Announce Quarterly Sales of $1.27 Billion Analysts Expect Diplomat Pharmacy (DPLO) Will Announce Quarterly Sales of $1.27 Billion
www.americanbankingnews.com - April 29 at 1:54 AM
Diplomat Pharmacy (DPLO) Expected to Announce Earnings of $0.21 Per ShareDiplomat Pharmacy (DPLO) Expected to Announce Earnings of $0.21 Per Share
www.americanbankingnews.com - April 27 at 11:24 PM
Critical Contrast: CVS Health (CVS) versus Diplomat Pharmacy (DPLO)Critical Contrast: CVS Health (CVS) versus Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - April 27 at 1:30 PM
Diplomat to Release Q1 2018 Operating Results, Host Conference Call on May 7Diplomat to Release Q1 2018 Operating Results, Host Conference Call on May 7
finance.yahoo.com - April 23 at 4:51 PM
Detailed Research: Economic Perspectives on Craft Brew Alliance, Herc, Diplomat Pharmacy, Western Gas Partners, LP, Stag Industrial, and Genesee & Wyoming — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on Craft Brew Alliance, Herc, Diplomat Pharmacy, Western Gas Partners, LP, Stag Industrial, and Genesee & Wyoming — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - April 23 at 8:40 AM
Analyzing Express Scripts (ESRX) and Diplomat Pharmacy (DPLO)Analyzing Express Scripts (ESRX) and Diplomat Pharmacy (DPLO)
www.americanbankingnews.com - April 15 at 11:30 PM
Diplomat Pharmacy (DPLO) Given Consensus Recommendation of "Hold" by BrokeragesDiplomat Pharmacy (DPLO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 15 at 8:17 AM
Diplomat Pharmacy (DPLO) Downgraded by BidaskClub to "Sell"Diplomat Pharmacy (DPLO) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 14 at 11:26 PM
Edited Transcript of DPLO presentation 7-Mar-17 9:35pm GMTEdited Transcript of DPLO presentation 7-Mar-17 9:35pm GMT
finance.yahoo.com - April 12 at 9:34 AM
Zacks: Brokerages Expect Diplomat Pharmacy (DPLO) Will Announce Quarterly Sales of $1.27 BillionZacks: Brokerages Expect Diplomat Pharmacy (DPLO) Will Announce Quarterly Sales of $1.27 Billion
www.americanbankingnews.com - April 12 at 1:45 AM
 Brokerages Anticipate Diplomat Pharmacy (DPLO) Will Post Earnings of $0.22 Per Share Brokerages Anticipate Diplomat Pharmacy (DPLO) Will Post Earnings of $0.22 Per Share
www.americanbankingnews.com - April 10 at 11:16 PM
Reviewing Diplomat Pharmacy (DPLO) and Walgreens Boots Alliance (WBA)Reviewing Diplomat Pharmacy (DPLO) and Walgreens Boots Alliance (WBA)
www.americanbankingnews.com - April 9 at 7:14 AM
BidaskClub Upgrades Diplomat Pharmacy (DPLO) to "Buy"BidaskClub Upgrades Diplomat Pharmacy (DPLO) to "Buy"
www.americanbankingnews.com - April 8 at 7:00 PM

SEC Filings

Diplomat Pharmacy (NYSE:DPLO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Diplomat Pharmacy (NYSE:DPLO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Diplomat Pharmacy (NYSE DPLO) Stock Chart for Monday, May, 28, 2018

Loading chart…

This page was last updated on 5/28/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.